BioWorld Science

Nov. 6, 2020

View Archived Issues

Three-for-two method predicts immune response

Read More

Saillant obtains preclinical proof of concept with ST-02 for heart failure

Read More

European Commission approves Forxiga for HFrEF

Read More

First patient with AML dosed in phase I/II study of RTX-240

Read More

Hinova Pharmaceuticals describes PROTAC androgen receptor degraders

Read More

CLR-131 shows preliminary activity in pediatric brain and solid tumors

Read More

New anti-PD-L1 antibodies patented by Scripps Korea Antibody Institute

Read More

Bioardis discovers CD73 inhibitors

Read More

Dizal (Jiangsu) Pharmaceutical presents new JAK1 inhibitors

Read More

[64Cu]PSMA I&T shows promise for PSMA-specific PET imaging

Read More

Medshine Discovery synthesizes new factor XIa inhibitors

Read More

Active pipeline of potential new lupus therapies unfolding as ACR begins

Read More

New study to evaluate CymaBay's MBX-2982 for hypoglycemia in type 1 diabetes

Read More

Oral mucositis treatment GC-4419 does not affect tumor control outcomes in phase II trial

Read More

Acurx reports phase IIa data on ibezapolstat in C. difficile infection

Read More

SYNB-8802 consumes GI oxalate in animals with acute hyperoxaluria

Read More

Preclinical data on EBS-LASV vaccine presented

Read More

[18F]AS3504073-00: a PET tracer for imaging mitochondrial fatty acid beta-oxidation in the heart

Read More

Phase I data presented for iCo-019, novel oral formulation of amphotericin B

Read More

Genmab to conduct phase III study of epcoritamab in DLBCL

Read More

Puma reports interim phase II data on neratinib in EGFR exon 18 mutated metastatic NSCLC

Read More

Phase II extension study of vebicorvir in HBV does not achieve meaningful SVR rates

Read More

Scientists identify distinct type of membranous nephropathy linked to protocadherin 7

Read More

CAN-COVID trial of canakinumab in patients with COVID-19 pneumonia and CRS misses endpoints

Read More